Evidence map›Paper›PMID 41645621›Full record

ArticleAmerican journal of epidemiology2026

Quantitative bias analyses to address measurement error in time-to-event endpoints.

Benjamin Ackerman, Ryan W Gan, Youyi Zhang, Jennifer Hayden, Jocelyn R Wang, Craig S Meyer, Juned Siddique, Jennifer L Lund, Janick Weberpals, Sebastian Schneeweiss and 9 more

Abstract read
In one paragraph

Article in American journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Benjamin AckermanJohnson & Johnson, Raritan, NJ, United States.ORCID 0000-0003-2522-6623
Ryan W GanJohnson & Johnson, Raritan, NJ, United States.
Youyi ZhangJohnson & Johnson, Raritan, NJ, United States.
Jennifer HaydenJohnson & Johnson, Raritan, NJ, United States.
Jocelyn R WangJohnson & Johnson, Raritan, NJ, United States.
Craig S MeyerJohnson & Johnson, Raritan, NJ, United States.
Juned SiddiqueDepartment of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
Jennifer L LundDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.ORCID 0000-0002-1108-0689
Janick WeberpalsDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Sebastian SchneeweissDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.ORCID 0000-0003-2575-467X
Til StürmerDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.ORCID 0000-0002-9204-7177
James RooseFlatiron Health, New York, NY, United States.
Omar NadeemDepartment of Hematology and Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
Noopur RajeCenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA, United States.
Sikander AilawadhiDepartment of Hematology, Mayo Clinic, Jacksonville, FL, United States.
Smith GiriDivision of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Laura HesterJohnson & Johnson, Raritan, NJ, United States.
Jason BrayerJohnson & Johnson, Raritan, NJ, United States.
Ashita S BataviaJohnson & Johnson, Raritan, NJ, United States.

Funding

the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS)
6 · The paper itself

Abstract

When using real-world data to construct an external comparator arm for a single-arm trial, there may be differences in how and when patients are assessed for disease between trial and real-world settings. Such differences can generate outcome measurement error when comparing time-to-event endpoints and lead to biased findings. Recent methods have been developed to mitigate measurement error bias in real-world endpoints; however, they rely on the existence of a validation sample, ie, data on a set of patients where both the "true" trial-like and "mis-measured" real-world measures are collected. We demonstrate how novel statistical methods can be leveraged as quantitative bias analyses (QBA) to contextualize real-world evidence findings when outcome measurement error is of concern, but validation samples are infeasible to collect. Quantitative bias analyses allow researchers to set plausible ranges for the amount of error when not directly measurable. We highlight how to conduct QBA with two recent methods, cumulative incidence curve correction and survival regression calibration, and illustrate how to generate plausible parameter values through simulation. We provide an illustrative QBA example in a cohort of real-world patients with newly diagnosed multiple myeloma and provide practical guidance to apply QBA for outcome measurement error and interpret results.

Indexed as

Endpoint DeterminationBiasData Interpretation, StatisticalHumansMultiple Myelomaendpointsexternal control armmeasurement errormisclassification biasoncologyquantitative bias analysisreal-world data (RWD)surveillance bias

Identifiers

PMID41645621
PMCPMC13537843

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.